Lycorine targets multiple myeloma stem cell‐like cells by inhibition of Wnt/β‐catenin pathway
- 13 March 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 189 (6), 1151-1164
- https://doi.org/10.1111/bjh.16477
Abstract
Multiple myeloma (MM) is characterised by the proliferation and accumulation of malignant plasma cells in the bone marrow. Despite the progress in treatment over the last few years, MM remains incurable and the majority of patients relapse. MM stem‐like cells (MMSCs) have been considered as the main reason for drug resistance and eventual relapse. Currently, therapeutic agents are not enough to eradicate MMSCs, and finding effective strategies to eradicate MMSCs may improve the outcome of patients. Here we showed that lycorine, a natural compound from the Amaryllidaceae species, effectively inhibits the proliferation of myeloma cells from cell lines or patients, mainly through decreasing ALDH1+ cells. Mechanistically, lycorine decreases the MMSC population through inhibition of the Wnt/β‐catenin pathway by reducing the β‐catenin protein level. Moreover, lycorine could overcome the increasing proportion of ALDH1+ cells caused by bortezomib (BTZ) treatment, and a combination BTZ and lycorine have a synergistic effect on anti‐myeloma cells. Furthermore, we found a similar reduction of MMSC characteristics by lycorine in BTZ‐resistant MM cells and primary CD138+ plasma cells. Collectively, our findings indicate lycorine as a promising agent to target MMSCs to overcome the drug resistance of BTZ, and that, alone or in combination with BTZ, lycorine is a potential therapeutic strategy for MM treatments.Keywords
Funding Information
- Research and Development (2018YFA0107800)
- National Natural Science Foundation of China (81600184, 81970195, 81920108004)
- Central South University
This publication has 44 references indexed in Scilit:
- TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancerEBioMedicine, 2019
- Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting optionsLeukemia, 2019
- Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Oncotarget, 2015
- Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomibLeukemia, 2015
- Stemness of B-cell Progenitors in Multiple Myeloma Bone MarrowClinical Cancer Research, 2012
- Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factorsLeukemia, 2012
- Tumorigenesis: Testing ground for cancer stem cellsNature, 2011
- Embryonic stem cells require Wnt proteins to prevent differentiation to epiblast stem cellsNature, 2011
- Critical Appraisal of the Side Population Assay in Stem Cell and Cancer Stem Cell ResearchCell Stem Cell, 2011
- Functional interaction of β-catenin with the transcription factor LEF-1Nature, 1996